BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19322653)

  • 1. Breast cancer-related preferences among women with and without BRCA mutations.
    Grann VR; Patel P; Bharthuar A; Jacobson JS; Warner E; Anderson K; Warner E; Tsai WY; Hill KA; Neugut AI; Hershman D
    Breast Cancer Res Treat; 2010 Jan; 119(1):177-84. PubMed ID: 19322653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
    Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
    Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
    Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2.
    Goldfrank D; Chuai S; Bernstein JL; Ramon Y Cajal T; Lee JB; Alonso MC; Diez O; Baiget M; Kauff ND; Offit K; Robson M
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2311-3. PubMed ID: 17119064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
    van Roosmalen MS; Stalmeier PF; Verhoef LC; Hoekstra-Weebers JE; Oosterwijk JC; Hoogerbrugge N; Moog U; van Daal WA
    J Clin Oncol; 2004 Aug; 22(16):3293-301. PubMed ID: 15310772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for hereditary breast cancer.
    Dent R; Warner E
    Semin Oncol; 2007 Oct; 34(5):392-400. PubMed ID: 17920893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
    van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
    J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on screening breast MRI in high-risk women.
    Boetes C
    Magn Reson Imaging Clin N Am; 2010 May; 18(2):241-7, viii. PubMed ID: 20494309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
    Dawson SJ; Price MA; Jenkins MA; McKinley JM; Butow PN; McLachlan SA; Lindeman GJ; Weideman P; Friedlander ML; Hopper JL; Phillips KA
    J Clin Oncol; 2008 Jan; 26(2):225-32. PubMed ID: 18040054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.